In health care crises, researchers can avoid waiting for clinical trial results by using data from health care systems to analyze the effectiveness of treatments for COVID-19 and other illnesses.
Broadly neutralizing antibodies are able to recognize multiple strains of HIV at once.
Naeblys/iStock via Getty Images Plus
Antiretroviral therapies for HIV, while extremely effective, need to be taken daily for life. Designing antibody treatments that need to be taken only once could improve compliance and reduce drug resistance.
While many immunocompromised and high-risk patients may benefit from AstraZeneca’s Evusheld, drug distribution and access have been uneven.
AP Photo/Ted S. Warren
Evusheld is an antibody drug from AstraZeneca intended to help prevent COVID-19 infection for immunocompromised and other vulnerable patients.
This image shows Ebola virus particles (red) budding from the surface of kidney cell (blue).
National Institute of Allergy and Infectious Diseases/Flickr